Temporal and pharmacological characterization of angiostatin release and generation by human platelets: implications for endothelial cell migration

PLoS One. 2013;8(3):e59281. doi: 10.1371/journal.pone.0059281. Epub 2013 Mar 15.

Abstract

Platelets play an important role in thrombosis and in neo-vascularisation as they release and produce factors that both promote and suppress angiogenesis. Amongst these factors is the angiogenesis inhibitor angiostatin, which is released during thrombus formation. The impact of anti-thrombotic agents and the kinetics of platelet angiostatin release are unknown. Hence, our objectives were to characterize platelet angiostatin release temporally and pharmacologically and to determine how angiostatin release influences endothelial cell migration, an early stage of angiogenesis. We hypothesized anti-platelet agents would suppress angiostatin release but not generation by platelets. Human platelets were aggregated and temporal angiostatin release was compared to vascular endothelial growth factor (VEGF). Immuno-gold electron microscopy and immunofluorescence microscopy identified α-granules as storage organelles of platelet angiostatin. Acetylsalicylic acid, MRS2395, GPIIb/IIIa blocking peptide, and aprotinin were used to characterize platelet angiostatin release and generation. An endothelial cell migration assay was performed under hypoxic conditions to determine the effects of pharmacological platelet and angiostatin inhibition. Compared to VEGF, angiostatin generation and release from α-granules occurred later temporally during platelet aggregation. Consequently, collagen-activated platelet releasates stimulated endothelial cell migration more potently than maximally-aggregated platelets. Platelet inhibitors prostacyclin, S-nitroso-glutathione, acetylsalicylic acid, and GPIIb/IIIa blocking peptide, but not a P2Y12 inhibitor, suppressed angiostatin release but not generation. Suppression of angiostatin generation in the presence of acetylsalicylic acid enhanced platelet-stimulated endothelial migration. Hence, the temporal and pharmacological modulation of platelet angiostatin release may have significant consequences for neo-vascularization following thrombus formation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Angiogenesis Inhibitors / pharmacology*
  • Angiostatins / pharmacology*
  • Aspirin / pharmacology
  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Cell Hypoxia
  • Cell Line
  • Cell Movement / drug effects*
  • Collagen / pharmacology
  • Culture Media, Conditioned / pharmacology
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Epoprostenol / pharmacology
  • Humans
  • Peptides / pharmacology
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • S-Nitrosoglutathione / pharmacology
  • Valerates / pharmacology
  • Vascular Endothelial Growth Factor A / pharmacology

Substances

  • 2,2-dimethylpropionic acid 3-(2-chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethylpropionyloxymethyl)propyl ester
  • Angiogenesis Inhibitors
  • Culture Media, Conditioned
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • VEGFA protein, human
  • Valerates
  • Vascular Endothelial Growth Factor A
  • S-Nitrosoglutathione
  • Angiostatins
  • Collagen
  • Epoprostenol
  • Adenine
  • Aspirin